These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 31585935)

  • 1. Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells.
    Mota Reyes C; Teller S; Muckenhuber A; Konukiewitz B; Safak O; Weichert W; Friess H; Ceyhan GO; Demir IE
    Clin Cancer Res; 2020 Jan; 26(1):220-231. PubMed ID: 31585935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.
    Shibuya KC; Goel VK; Xiong W; Sham JG; Pollack SM; Leahy AM; Whiting SH; Yeh MM; Yee C; Riddell SR; Pillarisetty VG
    PLoS One; 2014; 9(5):e96565. PubMed ID: 24794217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma.
    Rupp L; Dietsche I; Kießler M; Sommer U; Muckenhuber A; Steiger K; van Eijck CWF; Richter L; Istvanffy R; Jäger C; Friess H; van Eijck CHJ; Demir IE; Reyes CM; Schmitz M
    Front Immunol; 2024; 15():1378190. PubMed ID: 38629072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy.
    Michelakos T; Cai L; Villani V; Sabbatino F; Kontos F; Fernández-Del Castillo C; Yamada T; Neyaz A; Taylor MS; Deshpande V; Kurokawa T; Ting DT; Qadan M; Weekes CD; Allen JN; Clark JW; Hong TS; Ryan DP; Wo JY; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
    J Natl Cancer Inst; 2021 Feb; 113(2):182-191. PubMed ID: 32497200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of 2-arachidonoylglycerol in the regulation of the tumor-immune microenvironment in murine models of pancreatic cancer.
    Qiu C; Yang L; Wang B; Cui L; Li C; Zhuo Y; Zhang L; Zhang S; Zhang Q; Wang X
    Biomed Pharmacother; 2019 Jul; 115():108952. PubMed ID: 31078044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
    Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
    Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Cell-Derived IL1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer.
    Das S; Shapiro B; Vucic EA; Vogt S; Bar-Sagi D
    Cancer Res; 2020 Mar; 80(5):1088-1101. PubMed ID: 31915130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low intratumoral regulatory T cells and high peritumoral CD8(+) T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pancreatectomy.
    Liu L; Zhao G; Wu W; Rong Y; Jin D; Wang D; Lou W; Qin X
    Cancer Immunol Immunother; 2016 Jan; 65(1):73-82. PubMed ID: 26646849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic Stellate Cells Promote Tumor Progression by Promoting an Immunosuppressive Microenvironment in Murine Models of Pancreatic Cancer.
    Li C; Cui L; Yang L; Wang B; Zhuo Y; Zhang L; Wang X; Zhang Q; Zhang S
    Pancreas; 2020 Jan; 49(1):120-127. PubMed ID: 31856087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor.
    Oberstein PE; Dias Costa A; Kawaler EA; Cardot-Ruffino V; Rahma OE; Beri N; Singh H; Abrams TA; Biller LH; Cleary JM; Enzinger P; Huffman BM; McCleary NJ; Perez KJ; Rubinson DA; Schlechter BL; Surana R; Yurgelun MB; Wang SJ; Remland J; Brais LK; Bollenrucher N; Chang E; Ali LR; Lenehan PJ; Dolgalev I; Werba G; Lima C; Keheler CE; Sullivan KM; Dougan M; Hajdu C; Dajee M; Pelletier MR; Nazeer S; Squires M; Bar-Sagi D; Wolpin BM; Nowak JA; Simeone DM; Dougan SK
    Cancer Immunol Res; 2024 Sep; 12(9):1221-1235. PubMed ID: 38990554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
    Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
    Front Immunol; 2021; 12():643529. PubMed ID: 33679807
    [No Abstract]   [Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer.
    Heiduk M; Plesca I; Glück J; Müller L; Digomann D; Reiche C; von Renesse J; Decker R; Kahlert C; Sommer U; Aust DE; Schmitz M; Weitz J; Seifert L; Seifert AM
    JCI Insight; 2022 Nov; 7(22):. PubMed ID: 36509285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma.
    Chen B; Deng T; Deng L; Yu H; He B; Chen K; Zheng C; Wang D; Wang Y; Chen G
    BMC Cancer; 2021 Nov; 21(1):1211. PubMed ID: 34772375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy.
    Farren MR; Sayegh L; Ware MB; Chen HR; Gong J; Liang Y; Krasinskas A; Maithel SK; Zaidi M; Sarmiento JM; Kooby D; Patel P; El-Rayes B; Shaib W; Lesinski GB
    JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31830001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.
    Wang K; Zhan Y; Huynh N; Dumesny C; Wang X; Asadi K; Herrmann D; Timpson P; Yang Y; Walsh K; Baldwin GS; Nikfarjam M; He H
    Cancer Lett; 2020 Mar; 472():8-18. PubMed ID: 31857154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer.
    Dias Costa A; Väyrynen SA; Chawla A; Zhang J; Väyrynen JP; Lau MC; Williams HL; Yuan C; Morales-Oyarvide V; Elganainy D; Singh H; Cleary JM; Perez K; Ng K; Freed-Pastor W; Mancias JD; Dougan SK; Wang J; Rubinson DA; Dunne RF; Kozak MM; Brais L; Reilly E; Clancy T; Linehan DC; Chang DT; Hezel AF; Koong AC; Aguirre AJ; Wolpin BM; Nowak JA
    Clin Cancer Res; 2022 Dec; 28(23):5167-5179. PubMed ID: 36129461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deciphering the Crosstalk Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma.
    Siret C; Collignon A; Silvy F; Robert S; Cheyrol T; André P; Rigot V; Iovanna J; van de Pavert S; Lombardo D; Mas E; Martirosyan A
    Front Immunol; 2019; 10():3070. PubMed ID: 32038621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.
    Christmas BJ; Rafie CI; Hopkins AC; Scott BA; Ma HS; Cruz KA; Woolman S; Armstrong TD; Connolly RM; Azad NA; Jaffee EM; Roussos Torres ET
    Cancer Immunol Res; 2018 Dec; 6(12):1561-1577. PubMed ID: 30341213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.
    Kuwabara S; Tsuchikawa T; Nakamura T; Hatanaka Y; Hatanaka KC; Sasaki K; Ono M; Umemoto K; Suzuki T; Sato O; Hane Y; Nakanishi Y; Asano T; Ebihara Y; Kurashima Y; Noji T; Murakami S; Okamura K; Shichinohe T; Hirano S
    Cancer Sci; 2019 Jun; 110(6):1853-1862. PubMed ID: 30997706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.